Targeting signal transduction pathways for the treatment of Kaposi sarcoma

Janet L. Douglas; Henry B. Koon; Ashlee V. Moses

doi:10.1007/978-1-4419-1513-9_5

Targeting signal transduction pathways for the treatment of Kaposi sarcoma

Janet L. Douglas, Henry B. Koon, Ashlee V. Moses

Vaccine and Gene Therapy Institute

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Kaposi sarcoma (KS) is a multi-focal angioproliferative disease driven by infection of cells by Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV8). KSHV/HHV8 infection activates numerous sequential and parallel signaling pathways creating an angiogenic-inflammatory state that leads to the development of Kaposi sarcoma. These pathways can be grouped into KSHV/HHV8-specific pathways and cellular growth/angiogenic pathways that are pirated by KSHV/HHV8. Advances in our understanding of the pathogenesis of KS parallel the clinical development of signal transduction inhibitors. This chapter reviews the signaling pathways active in KSHV/HHV8-infected cells and discusses the use of clinical inhibitors of these pathways in the treatment of KS.

Original language	English (US)
Title of host publication	Molecular Basis for Therapy of AIDS-Defining Cancers
Publisher	Springer New York
Pages	79-93
Number of pages	15
ISBN (Print)	9781441915122
DOIs	https://doi.org/10.1007/978-1-4419-1513-9_5
State	Published - 2010

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1007/978-1-4419-1513-9_5

Cite this

@inbook{555a6203b0b34084984607c071105bb0,

title = "Targeting signal transduction pathways for the treatment of Kaposi sarcoma",

abstract = "Kaposi sarcoma (KS) is a multi-focal angioproliferative disease driven by infection of cells by Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV8). KSHV/HHV8 infection activates numerous sequential and parallel signaling pathways creating an angiogenic-inflammatory state that leads to the development of Kaposi sarcoma. These pathways can be grouped into KSHV/HHV8-specific pathways and cellular growth/angiogenic pathways that are pirated by KSHV/HHV8. Advances in our understanding of the pathogenesis of KS parallel the clinical development of signal transduction inhibitors. This chapter reviews the signaling pathways active in KSHV/HHV8-infected cells and discusses the use of clinical inhibitors of these pathways in the treatment of KS.",

author = "Douglas, {Janet L.} and Koon, {Henry B.} and Moses, {Ashlee V.}",

year = "2010",

doi = "10.1007/978-1-4419-1513-9_5",

language = "English (US)",

isbn = "9781441915122",

pages = "79--93",

booktitle = "Molecular Basis for Therapy of AIDS-Defining Cancers",

publisher = "Springer New York",

}

TY - CHAP

T1 - Targeting signal transduction pathways for the treatment of Kaposi sarcoma

AU - Douglas, Janet L.

AU - Koon, Henry B.

AU - Moses, Ashlee V.

PY - 2010

Y1 - 2010

N2 - Kaposi sarcoma (KS) is a multi-focal angioproliferative disease driven by infection of cells by Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV8). KSHV/HHV8 infection activates numerous sequential and parallel signaling pathways creating an angiogenic-inflammatory state that leads to the development of Kaposi sarcoma. These pathways can be grouped into KSHV/HHV8-specific pathways and cellular growth/angiogenic pathways that are pirated by KSHV/HHV8. Advances in our understanding of the pathogenesis of KS parallel the clinical development of signal transduction inhibitors. This chapter reviews the signaling pathways active in KSHV/HHV8-infected cells and discusses the use of clinical inhibitors of these pathways in the treatment of KS.

AB - Kaposi sarcoma (KS) is a multi-focal angioproliferative disease driven by infection of cells by Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV8). KSHV/HHV8 infection activates numerous sequential and parallel signaling pathways creating an angiogenic-inflammatory state that leads to the development of Kaposi sarcoma. These pathways can be grouped into KSHV/HHV8-specific pathways and cellular growth/angiogenic pathways that are pirated by KSHV/HHV8. Advances in our understanding of the pathogenesis of KS parallel the clinical development of signal transduction inhibitors. This chapter reviews the signaling pathways active in KSHV/HHV8-infected cells and discusses the use of clinical inhibitors of these pathways in the treatment of KS.

UR - http://www.scopus.com/inward/record.url?scp=84900070121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900070121&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1513-9_5

DO - 10.1007/978-1-4419-1513-9_5

M3 - Chapter

AN - SCOPUS:84900070121

SN - 9781441915122

SP - 79

EP - 93

BT - Molecular Basis for Therapy of AIDS-Defining Cancers

PB - Springer New York

ER -

Targeting signal transduction pathways for the treatment of Kaposi sarcoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this